We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+21.98%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$679M
AUM Growth
+$8.14M
Cap. Flow
+$879K
Cap. Flow %
0.13%
Top 10 Hldgs %
38.68%
Holding
124
New
21
Increased
25
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$18.7M
2
IFRX icon
InflaRx
IFRX
+$13M
3
VSTM icon
Verastem
VSTM
+$7.91M
4
AVIR icon
Atea Pharmaceuticals
AVIR
+$7.58M
5
ELEV
Elevation Oncology
ELEV
+$6.86M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$21.5M
2
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$9.81M
3
BLUE
bluebird bio
BLUE
+$9.14M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.01M
5
MRNA icon
Moderna
MRNA
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.72%
2 Financials 6.8%
3 Real Estate 0.3%
4 Consumer Discretionary 0.15%
5 Utilities 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
1
AnaptysBio
ANAB
$1.6B
$39.7M 5.84%
1,950,609
-81,952
-4% -$1.66M
TARS icon
2
Tarsus Pharmaceuticals
TARS
$2.56B
$32.1M 4.73%
1,779,158
-255,000
-13% -$4.05M
MIRM icon
3
Mirum Pharmaceuticals
MIRM
$6.89B
$29.4M 4.33%
1,137,107
-32,893
-3% -$875K
IMGN
4
DELISTED
Immunogen Inc
IMGN
$24.5M 3.61%
1,300,000
+25,147
+2% +$297K
IMCR icon
5
Immunocore
IMCR
$1.78B
$24.3M 3.58%
405,600
– –
BLUE
6
DELISTED
bluebird bio
BLUE
$24.3M 3.58%
369,141
-125,000
-25% -$9.14M
KALV
7
DELISTED
KalVista Pharmaceuticals
KALV
$23.9M 3.51%
2,651,393
– –
AXSM icon
8
Axsome Therapeutics
AXSM
$12.4B
$23M 3.39%
320,000
– –
EOLS icon
9
Evolus
EOLS
$394M
$22.5M 3.32%
3,097,399
-100,000
-3% -$863K
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$19M 2.8%
300,000
– –
FLG
11
Flagstar Bank National Association
FLG
$5.77B
$18.1M 2.66%
535,533
– –
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.37B
$17.2M 2.54%
2,450,000
+850,000
+53% +$6.82M
VRDN icon
13
Viridian Therapeutics
VRDN
$2.13B
$16.5M 2.43%
692,925
– –
ONC
14
BeOne Medicines Ltd
ONC
$33.8B
$15.2M 2.23%
85,000
– –
PCVX icon
15
Vaxcyte
PCVX
$7.89B
$15M 2.21%
300,000
– –
LLY icon
16
Eli Lilly
LLY
$1.07T
$14.1M 2.07%
30,000
– –
IFRX icon
17
InflaRx
IFRX
$256M
$12.9M 1.9%
+2,900,000
New +$13M
AZN icon
18
AstraZeneca
AZN
$263B
$12.2M 1.79%
85,000
– –
CTMX icon
19
CytomX Therapeutics
CTMX
$705M
$11.4M 1.67%
6,600,000
+506,968
+8% +$842K
AVIR icon
20
Atea Pharmaceuticals
AVIR
$379M
$11.3M 1.67%
3,026,455
+2,023,873
+202% +$7.58M
BCAB icon
21
BioAtla
BCAB
$5.59M
$11M 1.62%
73,482
+1,000
+1% +$172K
ALT icon
22
Altimmune
ALT
$539M
$9.71M 1.43%
2,750,000
– –
HRMY icon
23
Harmony Biosciences
HRMY
$2.04B
$9.54M 1.41%
271,200
-50,000
-16% -$1.73M
ZYME icon
24
Zymeworks
ZYME
$1.68B
$9.5M 1.4%
1,100,000
– –
MRNA icon
25
Moderna
MRNA
$21.5B
$9.32M 1.37%
76,700
-60,000
-44% -$8M
1
2 3 4 5

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $1.98B AUM 1.62% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return

Tang Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Tang Capital Management held 124 positions worth $679M, up 1.2% from $671M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tang Capital Management's Q2 2023 filing shows 21 new, 25 increased, 15 reduced and 25 closed positions. Its largest new stake was Rain Oncology Inc. Common Stock: 3,740,341 shares worth $4.49M. The largest sale was Novo Nordisk, an estimated $21.5M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Financials and Real Estate.

  • Tang Capital Management's largest Q2 2023 buy was Rain Oncology Inc. Common Stock: 3,740,341 shares worth $4.49M.
  • Tang Capital Management added most to Atea Pharmaceuticals in Q2 2023, an estimated $7.58M increase.
  • Tang Capital Management's biggest Q2 2023 reduction was bluebird bio, cutting an estimated $9.14M.
  • Tang Capital Management fully exited Novo Nordisk in Q2 2023, selling an estimated $21.5M.
  • Tang Capital Management's ten largest holdings make up 39% of its $679M portfolio in Q2 2023.
  • Tang Capital Management opened 21 new positions and closed 25 in Q2 2023.
  • Tang Capital Management's portfolio value rose 1.2% quarter-over-quarter to $679M.

Based on Tang Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.